Dai ichi Life Insurance Company Ltd Has $11.73 Million Position in Amgen Inc. $AMGN

Dai ichi Life Insurance Company Ltd lessened its position in Amgen Inc. (NASDAQ:AMGN) by 5.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,348 shares of the medical research company’s stock after selling 2,060 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Amgen were worth $11,733,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Anfield Capital Management LLC raised its stake in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC raised its position in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the period. Tower View Wealth Management LLC lifted its holdings in shares of Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 63 shares in the last quarter. Manning & Napier Advisors LLC grew its position in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new position in shares of Amgen in the 4th quarter valued at approximately $33,000. 76.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on AMGN. Morgan Stanley dropped their target price on shares of Amgen from $340.00 to $333.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 8th. BMO Capital Markets reiterated an “outperform” rating and issued a $400.00 price target on shares of Amgen in a report on Wednesday, July 1st. Royal Bank Of Canada restated a “positive” rating on shares of Amgen in a report on Thursday, June 18th. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research report on Friday, June 5th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research note on Friday, June 12th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Amgen has an average rating of “Hold” and a consensus target price of $356.62.

Amgen Trading Up 1.2%

NASDAQ AMGN opened at $376.04 on Friday. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock’s 50 day moving average price is $351.28 and its two-hundred day moving average price is $351.80. The stock has a market capitalization of $202.95 billion, a price-to-earnings ratio of 26.17, a PEG ratio of 3.76 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the business earned $4.90 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.